| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |

From the Institutes of Clinical Chemistry* and Gynecopathology,
University Hospital Eppendorf, Hamburg, Germany
Expression of the cell adhesion molecule CEACAM1 in melanomas is an independent factor for the risk of metastasis with a predictive value superior to that of tumor thickness. We have previously shown that CEACAM1 co-localizes at the tumor-stroma interface of invading melanoma masses with integrin ß3 and that these two adhesion molecules interact via the CEACAM1 cytoplasmic domain. To address the functional consequences of CEACAM1 expression, we investigated invasion and migration of melanocytic and melanoma cells that stably express CEACAM1 using two different in vitro systems. Here, we demonstrate that CEACAM1 expression markedly enhances cell invasion and migration. The enhanced invasion and migration of CEACAM1-transfected cells was dependent on the presence of Tyr-488 within the full-length cytoplasmic CEACAM1 domain. Treatment with anti-CEACAM monoclonal antibodies blocked CEACAM1-enhanced cell invasion and cell migration in a dose-dependent manner. Furthermore, the enhanced invasion and migration of CEACAM1-transfected melanoma cells was blocked by integrin-antagonizing RGD peptides. Expression of integrin ß3 induces the up-regulation of CEACAM1 in melanocytic MEL6 cells. These results strengthen the view that CEACAM1 and
vß3 integrin are functionally interconnected with respect to the invasive growth of melanomas.
This article has been cited by other articles:
![]() |
N. Kilic, L. Oliveira-Ferrer, S. Neshat-Vahid, S. Irmak, K. Obst-Pernberg, J.-H. Wurmbach, S. Loges, E. Kilic, J. Weil, H. Lauke, et al. Lymphatic reprogramming of microvascular endothelial cells by CEA-related cell adhesion molecule-1 via interaction with VEGFR-3 and Prox1 Blood, December 15, 2007; 110(13): 4223 - 4233. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Bogoevska, P. Nollau, L. Lucka, D. Grunow, B. Klampe, L. M. Uotila, A. Samsen, C. G. Gahmberg, and C. Wagener DC-SIGN binds ICAM-3 isolated from peripheral human leukocytes through Lewis x residues Glycobiology, March 1, 2007; 17(3): 324 - 333. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Bogoevska, A. Horst, B. Klampe, L. Lucka, C. Wagener, and P. Nollau CEACAM1, an adhesion molecule of human granulocytes, is fucosylated by fucosyltransferase IX and interacts with DC-SIGN of dendritic cells via Lewis x residues Glycobiology, March 1, 2006; 16(3): 197 - 209. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. Bamberger, J. Briese, J. Gotze, I. Erdmann, H. M. Schulte, C. Wagener, and P. Nollau Stimulation of CEACAM1 expression by 12-O-tetradecanoylphorbol-13-acetate (TPA) and calcium ionophore A23187 in endometrial carcinoma cells Carcinogenesis, March 1, 2006; 27(3): 483 - 490. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Colonna Cytolytic responses: cadherins put out the fire J. Exp. Med., February 20, 2006; 203(2): 261 - 264. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. Bamberger, V. Minas, S. N. Kalantaridou, J. Radde, H. Sadeghian, T. Loning, I. Charalampopoulos, J. Brummer, C. Wagener, C. M. Bamberger, et al. Corticotropin-Releasing Hormone Modulates Human Trophoblast Invasion through Carcinoembryonic Antigen-Related Cell Adhesion Molecule-1 Regulation Am. J. Pathol., January 1, 2006; 168(1): 141 - 150. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Klaile, M. M. Muller, C. Kannicht, B. B. Singer, and L. Lucka CEACAM1 functionally interacts with filamin A and exerts a dual role in the regulation of cell migration J. Cell Sci., December 1, 2005; 118(23): 5513 - 5524. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Briese, M. Oberndorfer, C. Patschenik, H. M. Schulte, A. Makrigiannakis, T. Loning, and A.-M. Bamberger Osteopontin Is Colocalized with the Adhesion Molecule CEACAM1 in the Extravillous Trophoblast of the Human Placenta and Enhances Invasion of CEACAM1-Expressing Placental Cells J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5407 - 5413. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |